Alzheimefs diseaserelated mutations in the ~resenilin-1 gene (PS11 are leadins to an elevated production of neurotoxic ß-amyloid 1-42 and may additionally enhance oxidatiie Stress. Here. we provide in viv0 evidence indicating that brains of transgenic mice expressing different human Alzheimer-linked PS1 mutations exhibit a reduced acüviiy of iwo antioxidant enzymes. For this purpose, mice transgenic for human PS1 and for single and multiple PS1 mutations were generated. Mice with multiple PS1 mutations showed a significantlydecreased activiiyof theantioxidant enzymes CuIZn superoxide dismuiase and glulathione reductase already at an age of 3-4months. As expected, this effect was less pronounced for the mice with a single PS1 mutation. By Contra-animals beaiing normal human PSI showed sionificantly elevated enzyme activities relative to non-transgenic liuermate controls. L------C -Keywom's Alrheimefs didisease; Reacüve oxygen species; Presenilin;Supemxide dismuwse; Gluinthione reductese; Lipid pemxidation Sevetal mutalionsof ihepresen.%n-I gene(PS1) massociated with wly-onset familial Alzheimer's disease (FAD) (for review see [X]). The finalpathogenic mechanism of PSI mutations r e m h still unknown, but seems tobe associated with altered protwlytic processing oP the amyloid precursor pmtein (APP). Seveml demonsnated an increased oxyradical prcduction, enhsnced mitochondrial dysfunction and enhnnced sensitivity to lipid peroxidation (LPO) in primary hippowmpai neumns £mm PSI mutant hock-in mice (PSI M146V) &er exposun? to Aß. In the present communicalion we describe the generation of three düierent types of ansgenic mice expressing either anomal humanPS1 cransgene(PS1wt)oraPSl m sgene bearing a single pathogemc mutation at ccdon M146 (PSI M146L) ormultiple FAD-specific mulations M146L + H163R + A246E + L286V + C410Y (PSI M5). since the wmbination of different PSI mutations shows additive effecls on Aßl-42 secretion [4]. We further addressed the question iP PSI mutaiions directly alter the activity of enzymes involved in lhe cellulnr defence mechanisms for oxidalive suess and whether this possible effect is more Conesponding author.
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Theprecisemechanisms by which theseaiterations lead to neuradegeneration in Alzheimer's d i e (AD) are still unknown. Recent findings link the genemtion of reactis*e oxygenspecies(R0S) with amyloiddepoGtionandaggregation as well as neuronal degeneration in AD. Synthetic Aß fmgnenlscan cause membme iipid pmxidation as well q an i n d p d u c t i o n o P R O S [I] . Thefrecradical hypothesisof Aß cymtoxicily is hurher supporledby theprotection of neuronal cells subjected to Aß ucament hy antioxidants, by inhibitors of oxidative eozyme metaboiism, or hy overexpression of supemxide dismume (SOD). Moreover, reeent data indicale a specific role of üee radicals in the pathomechanisrn of human PS1 muintions. Guo et al. [9] demonsnated an increased oxyradical prcduction, enhsnced mitochondrial dysfunction and enhnnced sensitivity to lipid peroxidation (LPO) in primary hippowmpai neumns £mm PSI mutant hock-in mice (PSI M146V) &er exposun? to Aß. In the present communicalion we describe the generation of three düierent types of ansgenic mice expressing either anomal humanPS1 cransgene(PS1wt)oraPSl m sgene bearing a single pathogemc mutation at ccdon M146 (PSI M146L) ormultiple FAD-specific mulations M146L + H163R + A246E + L286V + C410Y (PSI M5). since the wmbination of different PSI mutations shows additive effecls on Aßl-42 secretion [4] . We further addressed the question iP PSI mutaiions directly alter the activity of enzymes involved in lhe cellulnr defence mechanisms for oxidalive suess and whether this possible effect is more Conesponding author. Tel.: +49-69-798-293-77: fax: +4969-pmnOunced in the psI M5 mice.
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E-mailaddre+s:a.ecken@em.unl-franWun.de IA. Ecken). Mutagenesis of PSI was done using ihe SculptorTM in I Present address: NAP AG, Munich, Germany. vit0 mutagencsis System (Amersham, Fmce). nie wding region of PS1 was subcloned in Bluescript vector and mutations were introduced using oligonucleotides containing the desired mutation according to the protocol provided by the manufacturer.
In the ®rst transgenic expression vector, on position 146, methionin was replaced by leucin, this mutation leads to an age of onset of 45 years in FAD patients [14] . In addition, we created a new vector combining ®ve distinct FAD mutations (M146L 1 H163R 1 A246E 1 L286V 1 C410Y) in one expression construct (PS1 M5) [11] . The rationale behind this was to amplify eventual phenotypes in the transgenic mice due to additive effects of the different mutations, as it has been shown for the combination of two different mutations in PS1 (M146L and L286V, which are also included in the PS1 M5 mutations of the present study) with an additive effect on the Ab42 production. For the PS1 M5 construct subsequent rounds of mutagenesis were performed. All mutated sequences were veri®ed by sequence analysis [5] .
Transgene expression is under the control of the human HMG-CR-Promoter which represents a housekeeping-type promoter that shows a strong and ubiquitous expression pattern with high expression in neurons [6, 7] . The method of generation and characterization of PS1 transgenic animals has been described previously [6, 7] . Transgenic and nontransgenic mice were littermates or subsequent generation siblings and are therefore strain matched. PS1 transgenic mice showed normal growth and development, and revealed no apparent behavioural changes compared to littermate controls. Life duration of transgenic mice was not changed.
The comparison of mutant transgenic lines to a wild type line expressing normal human PS1 (PS1wt) suggested that mutations in PS1, and not simple overexpression of the transgene, were responsible for the cellular changes described in the following.
As already shown by other studies, transgenic mice overexpressing mutant PS1 show an elevation in Ab42, but they do not develop amyloid deposits by 24 months of age [3, 10] . This is in contrast to APP and APP/PS1 transgenic mice [10] . Accordingly, PS1 M146L and PS1 M5 mice do not develop amyloid plaques in the brain even at the age of 13 months [11] . Therefore, it is important to investigate more subtle changes at the cellular level reported in the present study.
For Western blotting, protein extracts from brain tissue of transgenic (PS1wt, PS1 M146L and PS1 M5) or non-transgenic littermate control mice were prepared. After gel electrophoresis (SDS-PAGE), PS1 proteins were identi®ed by immunoblotting using the antibody MAB1563 (Chemicon). Details of these assays have been described previously [7] .
All mice were investigated at an age of 3±4 months and were killed by decapitation. Brains were quickly removed and tissue samples without cerebellum were homogenized. Each of the following assays was performed with every individual of each group of mice (non-transgenic mice: n 15; mice transgenic for human PS1wt: n 10; PS1 M146L mice: n 10; PS1 M5 mice: n 7). Superoxide dismutase (SOD) activity was measured using the SOD-525 kit purchased by Calbiochem w (Bad Soden, Germany) according to the manufacturer's protocol. One SOD-525 activity unit is de®ned as the activity that doubles the autoxidation rate of the control blank (V sample =V control 2). Glutathione reductase (GR) activity was assayed using a commercially available kit by Calbiochem w . One GR unit is de®ned as the reduction of 1 mM of glutathione per minute at 258C and pH 7.6. Brain homogenates were incubated with 100 mM FeCl 3 (Merck, Darmstadt, Germany) or buffer as control for 30 min at 378C. After centrifugation, the supernatants were collected and tested for lipid peroxidation (LPO) by measuring the concentration of malondialdehyde (MDA). The LPO-586 kit, purchased from Calbiochem w , was used for this purpose. This kit takes advantage of a special chromogenic reagent which reacts speci®cally with MDA at a comparatively low temperature of incubation (458C). In order to assess whether human PS1 is expressed in the brain of the transgenic mice, we performed Western blot analysis of brain homogenates from transgenic mice and non-transgenic littermate controls. The Western blot was probed with a monoclonal antibody directed against the amino-terminal part of PS1. This antibody is speci®c for human PS1 since no signal of the endogenous PS1 is detectable in the homogenate of the non-transgenic mice (Fig. 1, lane 4) . All three different lines of transgenic mice show clear expression of the transgene in the brain. However, the proteolytic processing of transgenic PS1 is different between constructs. The characteristic amino-terminal fragment of PS1 is detectable in the brain of mice expressing PS1 M146L and PS1 wt (Fig. 1, lane 2,  3 ) with the appearance of small amounts of full-length PS1 M146L most likely due to saturation of processing events as described previously in transgenic mice and rats expressing high amounts of PS1 [7, 17] . However, multiple mutations in PS1 M5 resulted in a clear reduction in the N-terminal fragment and accumulation of full-length PS1 (Fig. 1, lane 1) . This is most likely not due to saturation of the processing since the levels of PS1 M5 expression are lower than the levels of PS1wt or PS1 M146L protein. Instead, the accumulation of full-length protein suggests that PS1 M5 has severe structural alterations which make it no longer a substrate for the presenilinase. It was previously reported that some mutations in PS1 are able to alter the cleavage pattern towards the increase of full-length protein in transfected cells and it has been shown recently that in lymphocytes of FAD patients with PS1 mutations the PS1 proteolytic processing is impaired [16] . However, a correlation between known pathological functions of presenilin and proteolytic processing could yet not be clearly established since the naturally occurring delta-exon 9 mutation is not processed, due to the lack of the cleavage site, but still leads to an increase in Ab1±42 production [15] .
Furthermore, Western-blot analysis of the different transgenic lines with a polyclonal antibody against the aminoterminus of PS1 (95/23, gift from C. Masters, Melbourne) which in addition to the transgenic human PS1 also detected the endogenous PS1 indicated that the levels of the transgenic PS1 slightly exceeded the level of endogenous murine PS1 (data not shown) [11] .
To elucidate the postulated relationship between PS1 mutation and oxidative stress, we investigated SOD activity in PS1 transgenic mice. SOD is considered as a primary defence against oxidative damage rapidly converting superoxide anion to hydrogen peroxide. Cytosolic superoxide dismutase (Cu±Zn SOD) was signi®cantly decreased in the brains of both types of transgenic mice carrying the PS1 mutations as shown in Fig. 2A (ANOVA, P , 0:05). The PS1 M146L mutation already reduced the activity of SOD by about 20% vs. PS1wt. The multiple PS1 mutations led to a further and signi®cant decrease of the enzymatic activity of SOD (®nal reduction about 28%).
In addition, we examined the activity of GR which plays an important part in the cellular antioxidant system by reducing oxidized glutathione. Again, GR was signi®cantly decreased over all three groups (ANOVA, P , 0:01). Mice with multiple PS1 mutations showed a signi®cantly decreased activity (about 27%) of the cerebral enzyme GR compared to PS1wt and to PS1 M146L mice. However, the difference in the reduction of GR activity between PS1wt mice and PS1 M146L mice was less pronounced.
Basal levels of lipid peroxidation (LPO) measured by the formation of MDA, were not signi®cantly different among the examined groups of mice (PS1wt: 13.4^0.49; PS1 M146L, 12.9^0.61; PS1 M5: 13.29^0.97; data represent concentration of MDA (nM/mg of protein) as means (SEM). However, PS1 mutations seem to slightly increase the sensitivity of brain cells to LPO after FeCl 3 stimulation by 7% (PS1 M146L) or 20% (PS1 M5) compared to PS1wt (see Fig. 2C ).
The combined results of the current study obtained with three different transgenic lines are in line with ®ndings of a completely independent study using hippocampal neurons of PS1-knock-in-mice which show increased vulnerability to lipid peroxidation when exposed to b-amyloid itself [9] . This also supports that the changes seen are resulting from expression of human PS1 and mutant PS1, suggesting that the transgenic integration site was not responsible, even if our study used only one transgenic mouse line of each transgene.
To determine whether overexpression of human PS1 links protection or vulnerability to oxidative damage, we investigated antioxidant enzyme activity and lipid peroxidation in brains of PS1wt mice and non-transgenic littermate controls. Basal levels of LPO did not differ between non-transgenic littermates and mice expressing human PS1wt. In contrast, PS1wt mice were signi®cantly less vulnerable to LPO induced by FeCl 3 than non-transgenic mice (see Table 1 ). Moreover, the activities of the antioxidant enzymes GR and SOD were signi®cantly enhanced (see Table 1 ). The detailed role of human PS1 in neurons is still unknown, but there is some evidence that indicates a protective role for this protein.
Roperch et al. [12] described enhanced levels of apoptosis as a result of downregulation of PS1 in transfected cells. In fact, overexpression of PS1 even protects cortical neurons from experimentally induced apoptosis [2] . Thus, our data support a protective effect of human PS1 and suggest a possible role in the regulation of antioxidative defence mechanisms.
To our knowledge, this is the ®rst study showing in vivo changes of antioxidant enzyme activities in brains from transgenic mice bearing single or multiple PS1 mutations. Consistent with the rationale that different PS1 mutations within the same molecule cause more dysfunction and higher Ab1±42 elevation than one alone [4] , we found a stronger impairment of antioxidant defence mechanisms in PS1 M5 than in PS1 M146L mice. Although the mechanism by which mutated PS1 exerts these effects require further studies, our data indicate an important defect induced by PS1 mutations, which very likely contributes to the enhanced vulnerability for neurodegeneration.
